The Technical Analyst
Seer, Inc. [SEER]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Seer, Inc. Price, Forecast, Insider, Ratings, Fundamentals & Signals
-2.21% $1.770
America/New_York / 24 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 114.65 mill |
| EPS: | -1.350 |
| P/E: | -1.310 |
| Earnings Date: | May 08, 2024 |
| SharesOutstanding: | 64.77 mill |
| Avg Daily Volume: | 0.499 mill |
| RATING 2024-04-24 |
|---|
| B- |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Neutral | |
| Return On Equity: | Sell | |
| Return On Asset: | Sell | |
| DE: | Neutral | |
| P/E: | Neutral | |
| Price To Book: | Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -1.310 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.22x |
| Company: PE -1.310 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 1.665 - 1.895 ( +/- 6.46%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-03-07 | Farokhzad Omid | Sell | 52 857 | Class A Common Stock |
| 2024-02-06 | Kogan Elona | Buy | 123 153 | Class A Common Stock |
| 2024-02-22 | Kogan Elona | Sell | 12 684 | Class A Common Stock |
| 2024-02-06 | Kogan Elona | Buy | 140 000 | Employee Stock Option (right to buy) |
| 2024-02-06 | Kogan Elona | Buy | 79 729 | Employee Stock Option (right to buy) |
| INSIDER POWER |
|---|
| 86.08 |
| Last 98 transactions |
| Buy: 6 813 760 | Sell: 922 350 |
Forecast:
16:00 - $1.775
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $1.775
Forecast 2: 16:00 - $1.775
Forecast 3: 16:00 - $1.775
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $1.770 (-2.21% ) |
| Volume | 0.204 mill |
| Avg. Vol. | 0.499 mill |
| % of Avg. Vol | 40.93 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For SEER
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
SEER
Seer, Inc., a life sciences company, engages in developing and commercializing products to decode the secrets of the proteome. It develops Proteograph Product Suite, an integrated solution that comprises consumables, an automation instrumentation, and software that allows researchers to conduct proteomic studies in therapeutic and diagnostic research, and clinical trials. The company intends to sell its products for research purposes, which cover academic institutions, life sciences, and research laboratories, as well as biopharmaceutical and biotechnology companies for non-diagnostic and non-clinical purposes. It has a collaboration agreement with Discovery Life Sciences, LLC. and the Salk Institute for Biological Studies. The company was formerly known as Seer Biosciences, Inc. and changed its name to Seer, Inc. in July 2018. Seer, Inc. was incorporated in 2017 and is headquartered in Redwood City, California.
Latest Press Releases
2024-04-23 16:05:00 - Press Release
Seer To Report First Quarter 2024 Financial Results On May 8, 2024
Redwood city, calif., april 23, 2024 (globe newswire) -- seer, inc. (nasdaq: seer), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced that it will report financial results for the first quarter 2024 on wednesday, may 8, 2024. company management will be webcasting a conference call beginning at 1:30 p.m. pacific time / 4:30 p.m. eastern time.
2024-02-29 16:05:00 - Press Release
Seer Reports Fourth Quarter And Full Year 2023 Financial Results and Provides Full Year 2024 Outlook
Enhanced access to the proteograph product suite and demonstrated its power with new customer data enhanced access to the proteograph product suite and demonstrated its power with new customer data
2024-02-21 16:05:00 - Press Release
Seer To Participate In The Td Cowen 44th Annual Health Care Conference
Redwood city, calif., feb. 21, 2024 (globe newswire) -- seer, inc. (nasdaq: seer), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced that the company will be participating in the upcoming td cowen 44th annual health care conference in boston, ma.
2024-02-06 08:00:00 - Press Release
Seer Proteograph™ Enables Unprecedented Genetic Marker Mapping For Proteogenomics Studies To Advance Drug And Biomarker Discovery
Study led by weill cornell medicine demonstrates identification of protein altering variants for population-scale protein quantitative trait loci (pqtl) studies
2024-02-01 16:05:00 - Press Release
Seer To Report Fourth Quarter And Full Year 2023 Financial Results On February 29, 2024
Redwood city, calif., feb. 01, 2024 (globe newswire) -- seer, inc. (nasdaq: seer), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced that it will report financial results for the fourth quarter and full year 2023 on thursday, february 29, 2024. company management will be webcasting a conference call beginning at 1:30 p.m. pacific time / 4:30 p.m. eastern time.
Latest News
2024-02-29 19:01:27 - Zacks Investment Research
Seer, Inc. (SEER) Reports Q4 Loss, Tops Revenue Estimates
Seer, Inc. (SEER) came out with a quarterly loss of $0.28 per share versus the Zacks Consensus Estimate of a loss of $0.35. This compares to loss of $0.36 per share a year ago.
2024-02-02 10:56:06 - Zacks Investment Research
Here's Why Seer, Inc. (SEER) Could be Great Choice for a Bottom Fisher
After losing some value lately, a hammer chart pattern has been formed for Seer, Inc. (SEER), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
2024-02-01 16:05:00 - GlobeNewsWire
Seer to Report Fourth Quarter and Full Year 2023 Financial Results on February 29, 2024
REDWOOD CITY, Calif., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced that it will report financial results for the fourth quarter and full year 2023 on Thursday, February 29, 2024. Company management will be webcasting a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
2023-12-21 16:05:00 - GlobeNewsWire
Seer to Present at the J.P. Morgan 42nd Annual Health Care Conference
REDWOOD CITY, Calif., Dec. 21, 2023 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced that the company will be participating in the upcoming J.P. Morgan 42nd Annual Health Care Conference in San Francisco, CA.
2023-11-10 09:00:00 - GlobeNewsWire
Seer to Present at the Canaccord MedTech, Diagnostics and Digital Health & Services Forum
REDWOOD CITY, Calif., Nov. 10, 2023 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced company management will be participating in the upcoming Canaccord MedTech, Diagnostics and Digital Health and Services Forum in New York, NY.
2023-11-07 22:31:02 - Seeking Alpha
Seer, Inc. (SEER) Q3 2023 Earnings Call Transcript
Seer, Inc. (NASDAQ:SEER ) Q3 2023 Results Conference Call November 7, 2023 4:30 PM ET Company Participants Carrie Mendivil - IR Omid Farokhzad - President, CEO David Horn - CFO Conference Call Participants Dan Brennan - TD Cowen Tejas Savant - Morgan Stanley Marta Nazarovets - JP Morgan Operator Good day, and thank you for standing by. Welcome to the Seer Third Quarter 2023 Earnings Conference Call.
2023-11-07 21:02:20 - Zacks Investment Research
Seer, Inc. (SEER) Reports Q3 Loss, Tops Revenue Estimates
Seer, Inc. (SEER) came out with a quarterly loss of $0.33 per share versus the Zacks Consensus Estimate of a loss of $0.38. This compares to loss of $0.38 per share a year ago.
2023-10-19 16:05:00 - GlobeNewsWire
Seer to Report Third Quarter 2023 Financial Results on November 7, 2023
REDWOOD CITY, Calif., Oct. 19, 2023 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a life sciences company commercializing a disruptive new platform for proteomics, today announced that it will report financial results for the third quarter of 2023 after market close on Tuesday, November 7, 2023. Company management will be webcasting a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
2023-09-28 20:10:56 - InvestorPlace
7 Contrarian Stocks to Buy for the High-Stakes Gambler
With the major equity indices printing some lackluster performances recently, the concept of contrarian stocks to buy might hit a bit differently now. Basically, with so many ideas printing red ink – and with analysts bashing that seemingly at every turn – a sudden reversal could yield tremendous profits.
2023-09-08 16:05:00 - GlobeNewsWire
Seer to Participate in Upcoming September Investor Conferences
REDWOOD CITY, Calif., Sept. 08, 2023 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a life sciences company commercializing a disruptive new platform for proteomics, today announced company management will be participating in the following investor conferences: